Diabetes Care (2020) 44(Supplement_1):S111S24
(13) These findings suggest a promising osteogenic role for GLP-1 therapies, especially in metabolic disease contexts
Given this paradigm, we have established an innovative resident nanozyme system with spontaneous sustainable catalytic activity for IDD treatment (Fig
Here are some common and less common side effects: Nausea Diarrhea Constipation Abdominal pain Vomiting Indigestion Fatigue Dizziness Headache In rare cases, more serious side effects can occur, such as pancreatitis and sarcopenia
This signaling pathway upregulates enzymes such as carnitine palmitoyl transferase 1, a key enzyme in -oxidation, while concurrently reducing the expression of lipogenesis-related genes, including SREBP-1c and FAS (195)
Byetta (exenatide): Twice-daily injectable